Event Led By Former Executive Secretary of Financial Action Task Force
BRIDGETOWN, Barbados–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/aml?src=hash” target=”_blank”gt;#amllt;/agt;–Five months after launching a chapter in Barbados to serve as an
anti-money laundering (AML) hub in the Caribbean, ACAMS has organized a
symposium addressing key issues and trends in AML compliance and
financial crime prevention to support financial professionals in the
region. Today’s event will be attended by representatives of both
private and public sectors from the Caribbean.
The one-day interactive symposium led by ACAMS subject matter experts
Rick McDonell, former executive secretary of the Financial Action Task
Force (FATF) and executive director of ACAMS, and Kieran Beer, chief
analyst and director of editorial content of ACAMS, will include topics
timely to international financial services professionals:
– Regulatory Update: The FATF Mutual Evaluation and Ongoing
– Keeping Current: Staying Ahead on Sanctions
– Best Practices for Obtaining and Maintaining Correspondent Banking
– Managing the AML Risks of New Payment Systems Including FinTech and
Barbados is a member of the Caribbean Financial Action Task Force, the
regional FATF group, whose purpose is to conduct assessments of the
effectiveness of the regime in member countries for anti-money
laundering and combatting the financing of terrorism (AML/CFT).
“This symposium will provide a practical opportunity to share best
practices on what constitutes a robust and compliant anti-money
laundering and counter-terrorist financing system, and the symposium’s
highly respected speakers will address those issues,” said Rick
McDonell. During his tenure at the FATF, McDonell helped develop the
standardized country assessment methodology which is now used to assess
all 195 member jurisdictions of the FATF global network.
“It’s valuable for financial crime professionals to stay up-to-date on
compliance requirements and regulatory updates in order to combat
emerging threats in the region,” said Rohit Sharma, president and
managing director of ACAMS. “ACAMS has a significant presence in the
region and is committed to supporting a culture of compliance in the
Caribbean through partnerships, training and knowledge sharing.”
About the Association of Certified Anti-Money Laundering Specialists®
ACAMS is a member of Adtalem Global Education (NYSE: ATGE), a global
education provider headquartered in the United States. ACAMS is the
largest international membership organization dedicated to enhancing the
knowledge and skills of anti-money laundering (AML) and financial crime
professionals from a wide range of industries. Its CAMS certification is
the most widely recognized AML certification among compliance
professionals worldwide. Visit acams.org for more information.
About Adtalem Global Education
The purpose of Adtalem Global Education is to empower students to
achieve their goals, find success, and make inspiring contributions to
our global community. Adtalem Global Education Inc. (NYSE: ATGE; member
S&P MidCap 400 Index) is a leading global education provider and the
parent organization of Adtalem Educacional do Brasil (IBMEC, Damásio and
Wyden institutions), American University of the Caribbean School of
Medicine, Association of Certified Anti-Money Laundering Specialists,
Becker Professional Education, Chamberlain University, EduPristine, Ross
University School of Medicine and Ross University School of Veterinary
Medicine. For more information, please visit adtalem.com
and follow us on Twitter (@adtalemglobal)
Agritek Holdings, Inc. Announces Proposed Completion Date of Apex Extractions Acquisition Including Assets, Brands and Distribution Into Wholly Owned Subsidiary
LOS ANGELES, CA, Jan. 22, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Agritek Holdings, Inc. (AGTK) www.AgritekHoldings.com, a fully integrated, active real estate investor for the cannabis sector and consultant for multiple cannabis brands, today announced that the Company expects to complete the acquisition of certain assets of Apex Extractions including brands and distribution licenses into a wholly owned subsidiary of Agritek Holdings by February 2020. Apex is a California based licensed manufacturer and distributor of over eleven Cannabis Cup award-winning brands (www.Apexextractions.com).
The highly anticipated acquisition brings together one of the most recognized cannabis brands in California with licensed manufacturing facilities in Oakland, California as a wholly owned subsidiary with immediate access to the public markets. Agritek Holdings is presently applying for a name change post acquisition to reflect the company’s pure real estate holdings model as Apex will represent the cannabis brands, assets, revenue and distribution model as the subsidiary. Both Companies will benefit investors strategically with the “new” Agritek Holdings seeking to purchase and lease back additional industrial zoned and innovative properties for cannabis operators with Apex and its partners acting as tenants and licensee’s for manufacturing, retail and cultivation operations in multiple legal jurisdictions.
“Under our new proposed acquisition structure, Apex will continue to provide manufacturing and distribution of our leading brands initially in California with revenue flowing through our subsidiary as Agritek, our parent and holding company will act as our real estate partner funding operations as we expand to multiple jurisdictions creating a perfect synergy for the sector,” stated Scott Benson, CEO of Agritek Holdings.
Approval of the executed definitive agreement and asset acquisition and name change is subject to the standard due diligence process and compliance for transactions approved for trading by OTC Markets.
About Agritek Holdings, Inc.
Agritek Holdings, Inc. (www.AgritekHoldings.com), is a fully integrated, active real estate investor and advisor in the legal cannabis sector. Specifically, Agritek Holdings provides strategic capital and functional expertise to accelerate the commercialization of its diversified portfolio of cannabis related holdings. Currently, the Company is focused on three high-value segments of the cannabis market, including real estate investment, intellectual property/brands, and infrastructure, with operations in three U.S. States, Canada, and Puerto Rico. Agritek Holdings, Inc. presently owns or manages cannabis properties in Colorado, Puerto Rico and Canada and has licenses with permitted facilities in California approved for cultivation as well as manufacturing capabilities. The company owns several Hemp and cannabis brands for distribution including “Hemp Pops”, Hemp oil wellness products, “Higher Society” and “California Premiums”. Agritek Holdings Inc. does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act.
About Apex Extractions
Founded in February 2017, Apex Solutions was one of the first licensed, recreational cannabis manufacturers established when legalization occurred in the state of California. So far in 2019, Apex Extractions’ concentrates and pens have already won 10 High Times Cannabis Cup awards and last month the company introduced the Apex Solutions Fresh Club subscription delivery service. Apex additionally provides bulk concentrates to some of the largest brands in California.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Agritek Holdings, Inc. to be materially different from the statements made herein.
Agritek Holdings, Inc.
SpeakEasy Cannabis Club Ltd Reveals Strategic Direction For 2020
SpeakEasy Cannabis Club Ltd. (CSE: EASY) (Frankfurt: 39H) (the “Company” or “SpeakEasy“), a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act, today revealed its plans to transform into a global cannabis brand by applying large scale commercial farming principles to burgeoning national and international markets. Building on the Geen family’s 100 years of experience farming cherries, apples, ginseng and peaches, the Company plans to cultivate small batch, high quality craft cannabis and, subject to receipt of all applicable licences from Health Canada, produce approximately 70,000kg of outdoor sun-grown cannabis in 2020.
The Company expects that in 2020 there will be a shift in the global cannabis industry into a consumer-packaged goods industry with the introduction of new product categories and increased segmentation in existing ones. SpeakEasy has developed a business model that adds core value and amplifies brand differentiation in what is expected to be a flourishing market. Building on its solid foundation, the Company will identify international revenue sources and replicate its operations in emerging global cannabis markets.
Moving from speculation to reality, a correction in the industry has taken place as dissatisfaction with current product offerings impacts sales projections. By focusing on both indoor and outdoor cultivation and following the proven business frameworks of successful multinational farming cooperatives, SpeakEasy is positioned to cultivate premium BC cannabis and deliver significant revenues and cost efficiencies.
“The blueprint to agricultural success must begin with proper site selection. It is the foundation of all farming,” says SpeakEasy Founder, Marc Geen. “As a fourth generation farmer benefitting from the Okanagan’s fertile golden mile, we have an intrinsic understanding of the land and how to cultivate and grow.”
Indoor cultivation: SpeakEasy completed the construction of its 10,000 sq. ft. purpose built indoor facility in November 2019, bringing its total indoor growing space, once all the buildings are completed, to approximately 63,000 sq. ft. SpeakEasy applies craft cultivation techniques to grow premium craft cannabis in this space. To target the luxury cannabis market large corporations have started to invest in small batch producers, for instance Aphria purchased B.C company Broken Coast for $230m. With legacy growers benefitting from over 100 years of combined experience, SpeakEasy is well positioned to produce high margin small batch cannabis.
SpeakEasy founder Marc Geen says, “We don’t need to look far to see what happens in a mature cannabis market, high quality, actual high quality becomes the norm and sells well, mid or low quality simply does not sell. SpeakEasy is fixated on producing the best quality possible in our purpose built tried and true facilities.”
Outdoor cultivation: SpeakEasy projects that delivering cost efficiencies will be essential as cannabis transforms into a global consumer packaged goods industry. The Company projects that outdoor cultivation will enable it to produce trimmed flower for approximately $0.04 per gram and biomass for extraction at approximately $0.02 per gram. The Company has recently built an outdoor facility and has applied for an outdoor cultivation licence, which it anticipates receiving in Q1 2020.
CBD hemp plantation: SpeakEasy expects to plant a minimum of 50 acres of hemp in 2020 in an outdoor field, that was fully prepared in the fall of 2019. By controlling input costs by producing their own hemp, coupled with innovative extraction methods, SpeakEasy projects its cost to produce a 80% CBD distillate to be under $1,000/kg versus current prices that can run as high as $30,000/kg, allowing the Company to enter global markets at a competitive price.
Consumer facing brands: SpeakEasy is building real brands for the future with the development of multiple consumer products, including high THC flower, medical cannabis and CBD products. SpeakEasy believes that to succeed in the competitive cannabis market, brands must be developed authentically to engage and resonate with consumers. By harnessing legacy growers and an extensive library of unique genetics, the Company will be able to produce high quality small batch cannabis indoors and exceptionally low cost flower for extraction purposes outdoors.
Online sales: Domestic cannabis markets have been restricted by availability and supply chain issues. To meet the needs of the modern consumer and improve supply chain resilience, SpeakEasy has undertaken projects to become vertically integrated through BWell – the first CBD e-commerce marketplace in Canada. The initiative will enable the Company to acquire new customers at a low cost and expand upon a business model that mirrors Amazon’s marketplace approach. Management expects that this marketplace approach will advance SpeakEasy’s aim to become a recognized household name across North America.
Extraction processing: The introduction of new product categories has the potential to add significant revenue streams for companies with extraction capabilities. To capitalize on this opportunity SpeakEasy is developing a state-of-the art 26,000 sq. ft. extraction facility, which it expects to complete in Q3 2020. Once in service, the Company expects to augment operations by processing up to 350,000kg of cannabis annually.
2020 Timeline of Project Completion Dates:
Q1 – Outdoor License Amendment, Hemp Field License & First Harvest
Q2 – Outdoor Planted, Hemp Fields Planted
Q3 – Extraction/Processing & Cooler Building
Q4 – Product on shelves
“We started out differently than most by beginning everything we do with the simple question, what do our customers want, and we built everything with that in mind. Consumer wants and needs cannot be an afterthought or something we figure out later, it is the sole purpose for everything we do,” says Founder, Marc Geen. “Quality, genetics, product types and pricing all need to make a formula that works to supply our customers. SpeakEasy has never been a stock play, it has always been a business built from the ground up with a long bright future in front of it.”
SOURCE Speakeasy Cannabis Club Ltd.
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma’s Scientific Advisory Board (SAB).
Dr. Kaiser is currently the Managing Director with the Healthcare Industry Group at Alvarez and Marsal, a leading global professional services firm. Most recently, Dr. Kaiser was the President and CEO of the $2.2 billion Temple University Health System (“Temple”), Dean of Temple University’s Lewis Katz School of Medicine, and Senior Executive Vice President for Health Sciences at Temple University. Among his many accomplishments at Temple was the acquisition of the Fox Chase NCI-designated Comprehensive Cancer Center, the development of a number of programs, including the number one lung transplant program in the country, a nationally recognized program in pulmonary hypertension, in addition to growing programs in cardiovascular surgery, thoracic surgery, neurosurgery, and orthopedic surgery. Before joining Temple University in 2011, Dr. Kaiser served as the President of the University of Texas Health Science Center at Houston, the largest of six health-related campuses at the University of Texas.
“With decades of academic and senior executive experience in medicine and the delivery of healthcare in the United States, Dr. Kaiser brings substantial depth and strength to our Board of Directors,” said Raza Bokhari, MD, Executive Co-Chairman and CEO of FSD Pharma. “Dr. Kaiser has already contributed immensely as Chairman of our world-class Scientific Advisory Board, where his input has been very meaningful in shaping our Biosciences strategy to focus on assembling synthetic compounds that target the CB2 receptors of the endocannabinoid system of the human body. As a Director, we are relying on his leadership and sage counsel as we continue to double down on our Biosciences effort to eventually bring to market prescription-based drugs by conducting rigorous FDA-approved clinical trials.”
Dr. Kaiser stated, “I am truly honored to join the outstanding leadership group that Dr. Bokhari has assembled at FSD Pharma. I am impressed with the entrepreneurial spirit that this company brings and look forward to a number of exciting developments in the months to come. It is a privilege to work with a group so committed to building a successful and innovative company based on the foundation created by its founders.”
Dr. Kaiser graduated AOA (Alpha Omega Alpha Honor Medical Fraternity) from the Tulane University School of Medicine in 1977 and completed his residency in general surgery as well as a fellowship in surgical oncology at the University of California, Los Angeles. He then completed a residency in cardiovascular and thoracic surgery at the University of Toronto. Following that, he held positions as attending thoracic surgeon at Memorial Sloan-Kettering Cancer Center and Assistant Professor of Surgery at Cornell University Medical College (both New York City) and subsequently as Associate Professor (with tenure) at the Washington University School of Medicine (St. Louis). At the University of Pennsylvania, Dr. Kaiser held a variety of positions, including chief of general thoracic surgery, founder and director of the university’s lung transplantation program, director of its Center for Lung Cancers and Related Disorders, and co-director of the Thoracic Oncology Laboratory. In 2001, following a national search, he was named the John Rhea Barton Professor and Chair of the Department of Surgery as well as Surgeon in Chief for the University of Pennsylvania Health System. In 1997, Dr. Kaiser was named as the first recipient of the Eldridge Eliason Professorship of Surgery endowment at the Perelman School of Medicine at the University of Pennsylvania.
Dr. Kaiser is author or co-author of 17 books and more than 300 original papers, and he serves on multiple editorial boards, including the Annals of Surgery, the world’s leading surgical journal, the American Journal of Surgery, and the European Journal of Cardiothoracic Surgery. Dr. Kaiser has served in a number of leadership capacities for professional societies and associations and has been a director of both the American Board of Surgery and the American Board of Thoracic Surgery. In 2005, he was elected to the National Academy of Medicine.
SOURCE FSD Pharma Inc.
Cannabis3 weeks ago
Flora Enters Into Agreement to Acquire Kasa Wholefoods Company S.A.S.
Cannabis3 weeks ago
HEXO CORP. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against HEXO Corp.
Cannabis4 weeks ago
Hemp, Inc. CEO, Bruce Perlowin, Featured In Havasu News Coverage About Kins Communities
Cannabis3 weeks ago
Top Strike Announces 2020 Second Quarter Financial Results and Provides Corporate Activity and Update
Cannabis3 weeks ago
MediPharm Labs Receives Licence Amendment to Permit Use of Expanded Canadian Facility for Private Label and White Label Production and R&D
Cannabis2 weeks ago
Hightimes Holding Corp. names former Overstock.com President as new CEO as it readies itself for Commerce
Cannabis4 weeks ago
HEXO CORP. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against HEXO Corp.
Cannabis3 weeks ago
Hemp, Inc. Applauds USDA’s New Insurance Option For Hemp